免疫检查点抑制剂联合抗血管生成药物治疗晚期非小细胞肺癌的研究进展

基金项目: 四川省自然科学基金项目

Progress of immune checkpoint inhibitors combined with anti-angiogenic drugs in the treatment of advanced non-small cell lung cancer

摘要: 免疫检查点抑制剂(immune checkpoint inhibitors，ICIs)的应用改善晚期非小细胞肺癌（non-small cell lung cancer，NSCLC）患者的预后。然而，仍有部分患者未能从中获益。近年来，研究证明抗血管生成药与ICIs联合可增强抗肿瘤效应，国内外指南中也建议晚期NSCLC患者可采用ICIs联合抗血管治疗方案。因此，本文就ICIs与抗血管生成药物联合治疗晚期NSCLC的作用机制和最新临床研究进行综述，以期为晚期NSCLC的治疗提供参考。
- 非小细胞肺癌 /
- 免疫检查点抑制剂 /
- 抗血管生成药物
Abstract: The use of immune checkpoint inhibitors (ICIs) improves the prognosis of patients with advanced non-small cell lung cancer (NSCLC). However, some patients still fail to benefit from them. In recent years, studies have demonstrated that the combination of antiangiogenic agents with ICIs can enhance the antitumor effect, and guidelines at home and abroad have also suggested that the combination of ICIs with antiangiogenic regimens can be used in patients with advanced NSCLC. Therefore, this article reviews the mechanism of action and the latest clinical studies on the combination of ICIs and anti-angiogenic drugs in the treatment of advanced NSCLC, with a view to providing reference for the treatment of advanced NSCLC.
- Non-small cell lung cancer /
- Immune checkpoint inhibitors /
- Anti-angiogenic drugs